Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHOP + CMAB304
- Development stage
- Unknown
- Lead developer
- 3S Guojian Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
CHOP + CMAB304 is a chemoimmunotherapy combination regimen developed by Sunshine Guojian Pharmaceutical (formerly Shanghai CP Guojian) for the treatment of CD20-positive diffuse large B-cell lymphoma (DLBCL). The regimen combines the standard CHOP chemotherapy backbone—comprising cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone—with CMAB304 (marketed as Retuxira), a biosimilar of the anti-CD20 monoclonal antibody rituximab. CMAB304 targets the CD20 antigen on B-cells, facilitating cell death through immune-mediated mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The combination is intended to improve clinical outcomes compared to chemotherapy alone and has been evaluated in Phase III clinical trials in China.
- Brand names
- Retuxira
- Other names
- Retuxira + CHOPCMAB304 + CHOPR-CHOP
02
Targets
CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on CHOP + CMAB304.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHOP + CMAB304.